Buscar resultados de ensayos clínicos
Carcinoma, Neuroendocrine - 25 Studies Found
Estado | Estudiar |
Not yet recruiting |
Nombre del estudio: Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas Condición: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) Fecha: 2017-04-18 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas Condición: Fecha: 2024-05-18 |
Completed |
Nombre del estudio: KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Condición: Carcinoma, Neuroendocrine Fecha: 2014-08-21 Intervenciones: Drug: Selinexor Selective Inhibitor fo Nuclear Export (SINE) |
Recruiting |
Nombre del estudio: An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis Condición: Fecha: 2024-05-18 |
Recruiting |
Nombre del estudio: A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours Condición: Fecha: 2024-05-18 |
Completed |
Nombre del estudio: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Condición:
Fecha: 2005-06-07 Intervenciones:
|
Recruiting |
Nombre del estudio: SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma Condición:
Fecha: 2015-07-06 Intervenciones: Drug: SC-002 SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks |
Recruiting |
Nombre del estudio: Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin Condición: Neuroendocrine Carcinomas Fecha: 2016-02-18 Intervenciones: Drug: cisplatinum and everolimus Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 o |
Recruiting |
Nombre del estudio: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Condición: Neuroendocrine Carcinoma Fecha: 2016-02-17 Intervenciones: Drug: Everolimus Maintenance therapy Other Name: Afi |
Active, not recruiting |
Nombre del estudio: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial Condición: Neuroendocrine Carcinoma of the Lung and Thymus Fecha: 2012-03-20 Intervenciones:
|